DVS Sciences

According to the Piper Jaffray analysis, of the 54 total papers published using CyTOF technology, 25 of them, or 46 percent, were published in 2014.

NEW YORK (GenomeWeb) — Fluidigm said after the close of the market on Thursday that its third quarter revenues increased 62 percent year over year, or 35 percent organically.

NEW YORK (GenomeWeb News) – Fluidigm reported after the close of the market Monday that its first quarter revenues increased 77 percent year over year, driven by strong instrument sales as well as contributions from a recent acquisition.

Two research teams have separately developed new imaging mass spec technologies for targeted protein measurements in tissue.

Fluidigm said this week that it has agreed to acquire mass cytometry firm DVS Sciences for roughly $207.5 million in company common stock and cash.

NEW YORK (GenomeWeb News) – Fluidigm said today that it has agreed to acquire mass cytometry firm DVS Sciences for roughly $207.5 million in company common stock and cash.

Thermo Fisher Scientific and the Department of Systems Biology at the Technical University of Denmark last week announced a collaboration on technology and application development related to research into cellular protein signaling.

DVS Sciences this week introduced its CyTOF 2 Mass Cytometer instrument, an updated version of its original CyTOF mass cytometer. The company also introduced new MaxPar Panel Kits for use with the instrument.

A team led by researchers from Stanford University has developed a multi-omics approach for profiling individuals' immune systems.

German cytometry startup Zellkraftwerk has begun offering researchers early access to its Chipcytometry platform in advance of a planned fall sales release for the device.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.